A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis
NCT ID: NCT00890162
Last Updated: 2019-07-01
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
16 participants
Study Classification
INTERVENTIONAL
Study Start Date
2009-04-27
Study Completion Date
2019-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Background:
* Omalizumab is an approved drug for the treatment of asthma by the Food and Drug Administration.
* Researchers are now studying this drug in a double-blind placebo-controlled manner to assess efficacy in patients with idiopathic anaphylaxis (recurrent hypersensitive allergic episodes for which a cause is not identified).
* The study will improve understanding of the mechanisms involved in anaphylactic reactions as a response to the downregulation (a decrease in the number of receptors on the surface of cells) in mast cell (a resident cell with several types of tissues) activation, and lead to the development of strategies to better prevent or treat anaphylaxis.
Objectives:
* To determine whether treatment with omalizumab will reduce or prevent episodes of unprovoked anaphylaxis (an acute allergic reaction) in subjects with a history of idiopathic anaphylaxis.
* To assess pharmacodynamics (physiological effects of a drug) and identify patients with undiagnosed mastocytosis (rare disorders caused by too many mast cells).
* To investigate cellular and molecular mechanisms of signaling and the effect of omalizumab on mast cells or basophils (a cell in the leukocyte family that releases histamine, which affects allergic response) and explore other regulatory pathways that may be involved with modulation of mast cell degranulation.
Eligibility:
* Patients between 18 and 70 years of age who have been diagnosed with idiopathic anaphylaxis, a diagnosis that is made only after other causes of anaphylaxis have been considered.
* Patients with documented anaphylaxis episodes (mild to severe) at least six times within the past 1 year period, at least once within the last 4 months, and with at least one of the following:
* Elevated serum tryptase above baseline within 2 hours of the event.
* Emergency room visit with documented anaphylaxis without a known cause established by the acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (generalized hives, itching or flushing, swollen lips-tongue-throat) and at least one of the following: (1) respiratory compromise or gastrointestinal involvement (shortness of breath, wheeze-bronchospasm, throat tightness, low oxygen levels, nausea, vomiting, or abdominal pain); or (2) reduced blood pressure or associated symptoms of end-organ dysfunction (collapse, loss of consciousness, or loss of bladder or bowel control).
* Hospitalization for anaphylaxis.
* Patients must provide a letter of referral, with copies of pertinent medical history and laboratory tests, from the prospective participant s local physician, and have the ability to give informed consent.
* Women with childbearing potential must have a negative pregnancy test, and must agree to practice abstinence or effective birth control from the start of the protocol and for 3 months following the last injection of the study drug.
Design:
* Participants will undergo a clinical evaluation, blood tests, and a bone marrow biopsy and aspirate.
* Participants will be randomized to either drug or placebo and will receive two doses of omalizumab or a matched placebo while hospitalized, followed by continued outpatient therapy, every 2 to 4 weeks, for up to 6 months.
* Participants will remain on the assigned regimen for 6 months or until they have experienced new onset of severe adverse event on one occasion within 24 hours of study medication that are related to the study drug, whichever comes first. At that time, the participant will be discontinued from drug administration.
* Omalizumab is an approved drug for the treatment of asthma by the Food and Drug Administration.
* Researchers are now studying this drug in a double-blind placebo-controlled manner to assess efficacy in patients with idiopathic anaphylaxis (recurrent hypersensitive allergic episodes for which a cause is not identified).
* The study will improve understanding of the mechanisms involved in anaphylactic reactions as a response to the downregulation (a decrease in the number of receptors on the surface of cells) in mast cell (a resident cell with several types of tissues) activation, and lead to the development of strategies to better prevent or treat anaphylaxis.
Objectives:
* To determine whether treatment with omalizumab will reduce or prevent episodes of unprovoked anaphylaxis (an acute allergic reaction) in subjects with a history of idiopathic anaphylaxis.
* To assess pharmacodynamics (physiological effects of a drug) and identify patients with undiagnosed mastocytosis (rare disorders caused by too many mast cells).
* To investigate cellular and molecular mechanisms of signaling and the effect of omalizumab on mast cells or basophils (a cell in the leukocyte family that releases histamine, which affects allergic response) and explore other regulatory pathways that may be involved with modulation of mast cell degranulation.
Eligibility:
* Patients between 18 and 70 years of age who have been diagnosed with idiopathic anaphylaxis, a diagnosis that is made only after other causes of anaphylaxis have been considered.
* Patients with documented anaphylaxis episodes (mild to severe) at least six times within the past 1 year period, at least once within the last 4 months, and with at least one of the following:
* Elevated serum tryptase above baseline within 2 hours of the event.
* Emergency room visit with documented anaphylaxis without a known cause established by the acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (generalized hives, itching or flushing, swollen lips-tongue-throat) and at least one of the following: (1) respiratory compromise or gastrointestinal involvement (shortness of breath, wheeze-bronchospasm, throat tightness, low oxygen levels, nausea, vomiting, or abdominal pain); or (2) reduced blood pressure or associated symptoms of end-organ dysfunction (collapse, loss of consciousness, or loss of bladder or bowel control).
* Hospitalization for anaphylaxis.
* Patients must provide a letter of referral, with copies of pertinent medical history and laboratory tests, from the prospective participant s local physician, and have the ability to give informed consent.
* Women with childbearing potential must have a negative pregnancy test, and must agree to practice abstinence or effective birth control from the start of the protocol and for 3 months following the last injection of the study drug.
Design:
* Participants will undergo a clinical evaluation, blood tests, and a bone marrow biopsy and aspirate.
* Participants will be randomized to either drug or placebo and will receive two doses of omalizumab or a matched placebo while hospitalized, followed by continued outpatient therapy, every 2 to 4 weeks, for up to 6 months.
* Participants will remain on the assigned regimen for 6 months or until they have experienced new onset of severe adverse event on one occasion within 24 hours of study medication that are related to the study drug, whichever comes first. At that time, the participant will be discontinued from drug administration.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy
NCT02966314
Idiopathic Angioedema
COMPLETED
PHASE4
Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
NCT01781637
Peanut Allergy
Food Allergy
COMPLETED
PHASE1/PHASE2
Omalizumab in the Treatment of Peanut Allergy
NCT00949078
Food Allergy
Peanut Allergy
COMPLETED
PHASE2
Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients
NCT01803763
Chronic Urticaria
Chronic Idiopathic Urticaria
Chronic Spontaneous Urticaria
COMPLETED
PHASE2/PHASE3
Omalizumab to Treat Hyper-IgE (Job's) Syndrome
NCT00260702
Hyper-IgE Syndrome
Job's Syndrome
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Anaphylaxis is a severe systemic reaction caused by release of mediators from mast cells and basophils. Manifestations include cutaneous, respiratory, cardiovascular, or gastrointestinal signs and symptoms. Although anaphylaxis is frequently attributed to exposure to specific foods, drugs, and insect venoms in sensitive individuals, a causative factor is not identified in 30% to 50% of patients with recurrent anaphylactic episodes (idiopathic anaphylaxis).
Currently, therapeutic options for the treatment of idiopathic anaphylaxis are limited with variable efficacy. This pilot study will examine the hypothesis that omalizumab (Xolair ) will decrease episodes of unexplained anaphylaxis in patients with idiopathic anaphylaxis. Omalizumab is approved for use in asthma. We will examine the safety profile and efficacy of omalizumab in patients with anaphylaxis. In addition, the study will investigate whether patients with anaphylaxis have unique molecular and cellular defects in mast cells that result in these cells being more susceptible to degranulation.
The study will enroll patients with idiopathic anaphylaxis. Patients will undergo a clinical evaluation, blood tests, and a bone marrow biopsy and aspirate. Patients will be randomized to either drug or placebo and will receive, in a double-blind placebo-controlled approach, 2 doses of omalizumab or a matched placebo while hospitalized, followed by continued outpatient therapy, every 2 to 4 weeks, for up to 6 months. Patients will remain on the assigned regimen if they have experienced anaphylactic events (post 24-hr window) determined to be unrelated to study drug or have been followed for 6 months, whichever comes first. These unrelated events would be determined by the PI not to jeopardize patient safety or restrict the use of additional therapy such as corticosteroids to control symptoms. After this point, the patient may be discontinued from drug administration until unblinding. This design ensures that no patient will have anaphylactic episodes while on placebo if other therapy is medically indicated. Research studies will be conducted to elucidate other markers or pathways of mast cell regulation.
The primary outcome will be a reduction in the number and timing of anaphylactic events during the randomized phase. Secondary outcomes will include a reduction in surface IgE receptors on basophils, identification of mutations in c-kit, and evaluation of the efficacy of omalizumab on other mediator-induced symptoms associated with anaphylaxis. The study will improve the understanding of the mechanisms involved in anaphylactic reactions as a response to the downregulation of mechanisms involved in mast cell activation that could, in turn, lead to development of strategies to better prevent or treat anaphylaxis.
Currently, therapeutic options for the treatment of idiopathic anaphylaxis are limited with variable efficacy. This pilot study will examine the hypothesis that omalizumab (Xolair ) will decrease episodes of unexplained anaphylaxis in patients with idiopathic anaphylaxis. Omalizumab is approved for use in asthma. We will examine the safety profile and efficacy of omalizumab in patients with anaphylaxis. In addition, the study will investigate whether patients with anaphylaxis have unique molecular and cellular defects in mast cells that result in these cells being more susceptible to degranulation.
The study will enroll patients with idiopathic anaphylaxis. Patients will undergo a clinical evaluation, blood tests, and a bone marrow biopsy and aspirate. Patients will be randomized to either drug or placebo and will receive, in a double-blind placebo-controlled approach, 2 doses of omalizumab or a matched placebo while hospitalized, followed by continued outpatient therapy, every 2 to 4 weeks, for up to 6 months. Patients will remain on the assigned regimen if they have experienced anaphylactic events (post 24-hr window) determined to be unrelated to study drug or have been followed for 6 months, whichever comes first. These unrelated events would be determined by the PI not to jeopardize patient safety or restrict the use of additional therapy such as corticosteroids to control symptoms. After this point, the patient may be discontinued from drug administration until unblinding. This design ensures that no patient will have anaphylactic episodes while on placebo if other therapy is medically indicated. Research studies will be conducted to elucidate other markers or pathways of mast cell regulation.
The primary outcome will be a reduction in the number and timing of anaphylactic events during the randomized phase. Secondary outcomes will include a reduction in surface IgE receptors on basophils, identification of mutations in c-kit, and evaluation of the efficacy of omalizumab on other mediator-induced symptoms associated with anaphylaxis. The study will improve the understanding of the mechanisms involved in anaphylactic reactions as a response to the downregulation of mechanisms involved in mast cell activation that could, in turn, lead to development of strategies to better prevent or treat anaphylaxis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Anaphylaxis
Hypotension
Bronchospasm
Angioedema
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Omalizumab
Subjects will receive two doses of Omalizumab while hospitalized, followed by continued outpatient therapy, every 2 to 4 weeks, for up to 6 months.
Group Type
ACTIVE_COMPARATOR
Epinephrine
Intervention Type
DRUG
Omalizumab (Xolair)
Intervention Type
DRUG
Placebo
Subjects will receive two doses of placebo while hospitalized, followed by continued outpatient therapy, every 2 to 4 weeks, for up to 6 months.
Group Type
PLACEBO_COMPARATOR
Epinephrine
Intervention Type
DRUG
Placebos
Intervention Type
DRUG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Epinephrine
Intervention Type
DRUG
Omalizumab (Xolair)
Intervention Type
DRUG
Placebos
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Subject must be at least 18 years of age and no older than 70 years of age.
Diagnosis of idiopathic anaphylaxis, a diagnosis of exclusion, assigned after other causes of anaphylaxis and other diseases in the differential diagnoses have been considered.
Anaphylaxis episodes (mild-severe) at least 6 times within the past 1 year period, documented according to medical records physician report, or patient report and 1 episode within the last 4 months, and with at least 1 of the following:
1. Elevated serum tryptase above baseline within 2 hours of the event.
2. Emergency room visit with documented anaphylaxis without an etiology established by the acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (e.g., generalized hives, pruritus or flushing, swollen lips-tongue-uvula) \[Grade 1\]\* and at least 1 of the following:
1. Respiratory compromise or gastrointestinal involvement (e.g., dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory flow, hypoxemia, nausea, vomiting, or abdominal pain \[Grade 2\]\*).
2. Reduced blood pressure or associated symptoms of end-organ dysfunction (e.g., hypotonia \[collapse\], syncope, or incontinence \[Grade 3\]\*).
3. Hospitalization for anaphylaxis: hospital records with documented anaphylaxis without known cause established by the acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (e.g., generalized hives, pruritus or flushing, swollen lips-tongue-uvula) \[Grade 1\]\*) and at least one of the following:
1. Respiratory compromise or gastrointestinal involvement (e.g., dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory flow, hypoxemia, nausea, vomiting, or abdominal pain \[Grade 2\]\*).
2. Reduced blood pressure or associated symptoms of end-organ dysfunction (e.g., hypotonia \[collapse\], syncope, or incontinence \[Grade 3\]\*).
4. Letter of referral, with copies of pertinent medical history and laboratory tests, from prospective study participant s local physician.
5. Ability to give informed consent.
6. Women of childbearing potential must have a negative beta-HCG serum or urine pregnancy test prior to each injection, and must agree to practice abstinence or effective contraception from initiation of the protocol and for 3 months following the last infusion of the study agent (effective contraception methods include abstinence; surgical sterilization of either partner, barrier methods such as diaphragm, condom, cap, or sponge; or hormonal contraception).
* Severity grading of anaphylaxis
Diagnosis of idiopathic anaphylaxis, a diagnosis of exclusion, assigned after other causes of anaphylaxis and other diseases in the differential diagnoses have been considered.
Anaphylaxis episodes (mild-severe) at least 6 times within the past 1 year period, documented according to medical records physician report, or patient report and 1 episode within the last 4 months, and with at least 1 of the following:
1. Elevated serum tryptase above baseline within 2 hours of the event.
2. Emergency room visit with documented anaphylaxis without an etiology established by the acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (e.g., generalized hives, pruritus or flushing, swollen lips-tongue-uvula) \[Grade 1\]\* and at least 1 of the following:
1. Respiratory compromise or gastrointestinal involvement (e.g., dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory flow, hypoxemia, nausea, vomiting, or abdominal pain \[Grade 2\]\*).
2. Reduced blood pressure or associated symptoms of end-organ dysfunction (e.g., hypotonia \[collapse\], syncope, or incontinence \[Grade 3\]\*).
3. Hospitalization for anaphylaxis: hospital records with documented anaphylaxis without known cause established by the acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (e.g., generalized hives, pruritus or flushing, swollen lips-tongue-uvula) \[Grade 1\]\*) and at least one of the following:
1. Respiratory compromise or gastrointestinal involvement (e.g., dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory flow, hypoxemia, nausea, vomiting, or abdominal pain \[Grade 2\]\*).
2. Reduced blood pressure or associated symptoms of end-organ dysfunction (e.g., hypotonia \[collapse\], syncope, or incontinence \[Grade 3\]\*).
4. Letter of referral, with copies of pertinent medical history and laboratory tests, from prospective study participant s local physician.
5. Ability to give informed consent.
6. Women of childbearing potential must have a negative beta-HCG serum or urine pregnancy test prior to each injection, and must agree to practice abstinence or effective contraception from initiation of the protocol and for 3 months following the last infusion of the study agent (effective contraception methods include abstinence; surgical sterilization of either partner, barrier methods such as diaphragm, condom, cap, or sponge; or hormonal contraception).
* Severity grading of anaphylaxis
Exclusion Criteria
1. Presence of conditions which, in the judgment of the investigator or the referring physician, may put the subject at undue risk for study participation or travel (such as an acute infection, severe thrombocytopenia, coronary artery disease, uncontrolled hypertension, congestive heart failure, chronic beta blocker therapy such as atenolol or metoprolol, or myeloproliferative disease).
2. History of malignancy
3. Known cause for anaphylaxis or flushing
4. Diagnosis of mastocytosis
5. Inability to provide informed consent
6. Inability or refusal to undergo a bone marrow biopsy and aspirate
7. HIV positive or other known immunodeficiency
8. Active or chronic hepatitis
9. Use of any other investigational agent within 30 days of the study
10. Current use of chronic-oral corticosteroids or other immunosuppressant medications
11. Pregnant or nursing women
12. Positive pregnancy test
13. IgE levels and subject s weight that cause dosing to be above dosing guidelines.
2. History of malignancy
3. Known cause for anaphylaxis or flushing
4. Diagnosis of mastocytosis
5. Inability to provide informed consent
6. Inability or refusal to undergo a bone marrow biopsy and aspirate
7. HIV positive or other known immunodeficiency
8. Active or chronic hepatitis
9. Use of any other investigational agent within 30 days of the study
10. Current use of chronic-oral corticosteroids or other immunosuppressant medications
11. Pregnant or nursing women
12. Positive pregnancy test
13. IgE levels and subject s weight that cause dosing to be above dosing guidelines.
Minimum Eligible Age
18 Years
Maximum Eligible Age
70 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Melody C Carter, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Thong BY, Cheng YK, Leong KP, Tang CY, Chng HH. Anaphylaxis in adults referred to a clinical immunology/allergy centre in Singapore. Singapore Med J. 2005 Oct;46(10):529-34.
Reference Type
BACKGROUND
Webb LM, Lieberman P. Anaphylaxis: a review of 601 cases. Ann Allergy Asthma Immunol. 2006 Jul;97(1):39-43. doi: 10.1016/S1081-1206(10)61367-1.
Reference Type
BACKGROUND
Neugut AI, Ghatak AT, Miller RL. Anaphylaxis in the United States: an investigation into its epidemiology. Arch Intern Med. 2001 Jan 8;161(1):15-21. doi: 10.1001/archinte.161.1.15.
Reference Type
BACKGROUND
Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol. 2007 Jun;119(6):1550-1. doi: 10.1016/j.jaci.2007.03.032. Epub 2007 May 3. No abstract available.
Reference Type
BACKGROUND
Constantine GM, Bressler PB, Petroni D, Metcalfe DD, Carter MC. Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis. J Allergy Clin Immunol Pract. 2019 Apr;7(4):1314-1316. doi: 10.1016/j.jaip.2018.07.041. Epub 2018 Aug 24. No abstract available.
Reference Type
BACKGROUND
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2009-I-0129.html
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09-I-0129
Identifier Type: -
Identifier Source: secondary_id
090129
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis
NCT07027163
COMPLETED
Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids
NCT00691873
COMPLETED
PHASE4
A Safety and Efficacy Study of Xolair in Peanut Allergy
NCT00086606
TERMINATED
PHASE2
Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model
NCT01040598
COMPLETED
PHASE1
E-B-FAHF-2, Multi OIT and Xolair (Omalizumab) for Food Allergy
NCT02879006
UNKNOWN
PHASE2
The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients
NCT01333293
COMPLETED
PHASE2/PHASE3
Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy
NCT02402231
UNKNOWN
PHASE2
Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy
NCT00329381
COMPLETED
PHASE4
The Effect of Xolair (Omalizumab) on Allergy Blood Cells
NCT00657891
COMPLETED
PHASE4
Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria
NCT02814630
COMPLETED
NA
A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)
NCT00866788
COMPLETED
PHASE2
Omalizumab to Treat Eosinophilic Gastroenteritis
NCT00084097
COMPLETED
PHASE2
Xolair Treatment for Milk Allergic Children
NCT00968110
COMPLETED
EARLY_PHASE1
E-B-FAHF-2, Multi OIT and Xolair for Food Allergy
NCT06103656
COMPLETED
PHASE2
A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
NCT01264939
COMPLETED
PHASE3
Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria
NCT01701583
COMPLETED
PHASE4
The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)
NCT00777764
COMPLETED
PHASE4
A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma
NCT00242359
WITHDRAWN
PHASE4
A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy
NCT00639691
COMPLETED
PHASE4
Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous Urticaria
NCT04944602
UNKNOWN
PHASE3
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL
NCT01544348
COMPLETED
PHASE1
The Effect of Omalizumab on Responses to Cat Allergen Challenge
NCT00604786
COMPLETED
NA
OIT and Xolair® (Omalizumab) in Cow's Milk Allergy
NCT01157117
COMPLETED
PHASE2
A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g
NCT00382148
COMPLETED
PHASE2
Omalizumab to Accelerate a Symptom-driven Multi-food OIT
NCT04045301
ACTIVE_NOT_RECRUITING
PHASE2